Managing Invasive Aspergillosis in haematological patients in the era of resistance PCR and increasing triazole resistance: a modelling study of different strategies

Invasive Aspergillosis (IA) is an opportunistic fungal infection with rising incidence among various patient populations. Patients treated for haematological malignancy with intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) are the population with the highest risk of developing IA and often receive antifungal chemoprophylaxis throughout treatment. Despite the use of chemoprophylaxis, incidence rates in this population remain substantial and IA continues to cause significant morbidity and mortality [1].

Source: International Journal of Antimicrobial Agents - November 2, 2018 Category: Drugs & Pharmacology Authors: R.J. van de Peppel, M.T. van der Beek, L.G. Visser, M.G.J. de Boer, J. Wallinga Source Type: research